In 2002, the Supreme Court of Canada developed a protocol to be applied whenever a search warrant was executed and some of the documents seized could potentially contain privileged information.
Canadian Patent No. 2,461,202 (the
202
Patent), which was asserted by Bristol-Myers Squibb Canada
Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company
(collectively,
BMS). The 202 Patent claims
the active ingredient apixaban and its use for the treatment and
prevention of thromboembolic disorders (blood clots).
Canadian Patent No. 2,791,171 (the
171
Patent), which was asserted by BMS and Pfizer Inc.
(collectively,
BMS & Pfizer). The 171
Patent claims tablet formulations of apixaban.
The Defendants only non-infringement allegation was that
the asserted claims of each of the patents were invalid.
The 202 Patent: compound and use claims valid and
infringed
Construction. The sole issue with respect
to construction of the asserted claims of the 202 Patent was
Press release content from Business Wire. The AP news staff was not involved in its creation.
CURO To Acquire Flexiti, A Leading Canadian POS/BNPL Lender, For $121 Million
February 1, 2021 GMT
WICHITA, Kan. (BUSINESS WIRE) Feb 1, 2021
CURO Group Holdings Corp. (NYSE: CURO) (“CURO”), a market leader in providing credit to non-prime consumers, today announced it has entered into an agreement to acquire Flexiti Financial Inc. (“Flexiti”), an emerging growth Canadian POS/BNPL provider. Under the terms of the agreement, CURO will acquire Flexiti for cash at closing of $85 million. The transaction also includes contingent consideration of up to $36 million based on the achievement of risk-adjusted revenue and origination targets over the next two years.
Revamped banking ombudsman could strengthen dispute resolution for customers theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.